TCR2 Therapeutics GAAP EPS of -$1.56 misses by $0.74

Stock Information for TCR2 Therapeutics Inc.

Loading

Please wait while we load your information from QuoteMedia.

More Recent News About TCR2 Therapeutics Inc.

TCR² Therapeutics Reports First Quarter 2023 Financial Results and Provides Corporate Update
TCR² Therapeutics Reports Inducement Grants Under Nasdaq Listing Rule 5635(c)(4)
SHAREHOLDER INVESTIGATION: Halper Sadeh LLC Investigates FOCS, ROCC, TCRR
TCR² THERAPEUTICS INVESTOR ALERT by the Former Attorney General of Louisiana: Kahn Swick & Foti, LLC Investigates Adequacy of Price and Process in Proposed Sale of TCR² Therapeutics Inc. - TCRR
STOCKHOLDER ALERT: The M&A Class Action Firm Continues its Investigation of the Merger - FRBA, SUMO, TCRR, MPB
SHAREHOLDER UPDATE: Halper Sadeh LLC Investigates ROCC, KBAL, ADAP, TCRR
SHAREHOLDER INVESTIGATION: Halper Sadeh LLC Investigates RADI, ADAP, TCRR
ALERT: The M&A Class Action Firm Continues its Investigation of the Merger - NBTB, FRBA, MPB, TCRR

Market data content copyright © QuoteMedia. Data delayed at least 15 minutes unless otherwise indicated (view Delay Times for all exchanges). Filings and Fundamentals by Morningstar. Insiders by Morningstar (USA) and SEDI (CDN). Analyst ratings by Zacks. Terms of Use.